Neurogene financials
$28.39−0.32%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 |
|---|---|---|---|
| Revenue | $0.00 | $925.0K | $0.00 |
| Gross profit | $0.00 | $925.0K | $0.00 |
| Gross margin | — | 100.0% | — |
| Operating income | -$103.3M | -$82.6M | -$55.6M |
| Net income | -$90.4M | -$75.1M | -$36.3M |
| Net margin | — | −8123.7% | — |
| Diluted EPS | $-4.24 | $-4.28 | $-39.56 |
| EBITDA | -$100.3M | -$79.4M | -$52.3M |
| Operating cash flow | -$77.2M | -$70.6M | -$51.4M |
| Free cash flow | -$78.4M | -$71.4M | -$51.7M |
| Diluted shares | 21.3M | 17.6M | 0.9M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|
| Cash & equivalents | $103.8M | $136.6M | $148.2M |
| Short-term investments | $165.2M | $175.8M | $48.9M |
| Total debt | $19.0K | $80.0K | $107.0K |
| Total assets | $288.6M | $335.7M | $222.6M |
| Total liabilities | $23.7M | $25.4M | $36.5M |
| Shareholders' equity | $264.9M | $310.4M | $186.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology